Northwestern Medicine investigators have uncovered a missing link behind the harmful effects of autoantibodies linked to ...

Expands AI-Driven Infrastructure Powering Evidence-Based Patient Activation Across Enterprise Healthcare SAN DIEGO and BIRMINGHAM, Ala., March 25, 2026 /PRNewswire/ -- Guideway Care today announced ...

Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

Dr.Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating deep ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking ...

Additions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical TrialsNORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences ...

National Student Accommodation Strategy will allow higher education institutes to make land available for private development ...

Hay fever sufferers have attempted various treatments and techniques. They have tried antihistamines, nasal sprays, air ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to ...

Gelatide supplement deliver a multi-pathway metabolic support formula designed to optimize fat oxidation, manage stress, and ...